Financial
Latest full-year results from official filings.
FY2025 revenue $2.71bn (+30.7%); operating margin 17.5%; net income $247.1m.
Cash $716.1m; debt $949.2m.
- Official results release · Insulet · 31 Dec 2025
Insulet: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Jul 2026: A US securities class action was filed against Insulet alleging it failed to disclose manufacturing control weaknesses ahead of its 2026 Omnipod pod corrections; the claims are unproven. No company response reported in the sources reviewed.
- Insulet Corporation Class Action Lawsuit · Robbins LLP (law firm notice) · 2 Jul 2026
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Insulet found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Mar 2026: Insulet corrected certain Omnipod 5 Pod lots after internal tubing tears could cause insulin under-delivery; FDA classed it Class I, with 29 serious injuries and no deaths reported. A further correction covering Omnipod 5, DASH and Eros Pods followed in May 2026.
- Insulin Pump Recall: Insulet Removes Certain Omnipod 5 Pods · US FDA · 18 Mar 2026
- Insulet Corporation Class Action Lawsuit (summarises 26 May 2026 correction) · Robbins LLP (law firm notice) · 2 Jul 2026
Contract performance
Contract delivery, go-lives, terminations and disputes.
No notable contract disputes, terminations or significant NHS/UK public sector contracts involving Insulet found in HSH's search of the last 24 months.